Ecovaxxin MS
Opinion
Mycoplasma synoviae, strain K588A, Live
Medicine
Veterinary
Opinion
On 6 November 2025, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the veterinary medicinal product Ecovaxxin MS, eye drops suspension, intended for chickens. The applicant for this veterinary medicinal product is Eco Animal Health Europe Limited.
Ecovaxxin MS is an immunological medicinal product containing Mycoplasma synoviae, strain K5885A, live as the active substance. The benefit of Ecovaxxin MS is the active immunisation of future layer and future breeder chickens from 4 weeks of age to reduce air sac lesions, foot pad lesions (synovitis), ovarian regressionand egg production losses caused by Mycoplasma synoviae infections.
The onset of immunity is 4 weeks after vaccination and the duration of immunity is 17 weeks after vaccination.
Ecovaxxin MS is generally well tolerated at the recommended dose.
Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Ecovaxxin MS and therefore recommends the granting of the marketing authorisation.
Note: Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.